Subcutaneous tocilizumab
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 93 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
Showing 1 to 10 of 93 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05725434 (ClinicalTrials.gov) | February 6, 202320230206 | 2/2/202320230202 | A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis A Study to Evaluate Usability of SubcutaneousAuto-injector of CT-P47 in Patients With Active Rheumat ... | A Single-arm, Open-label, Multiple-dose, Phase 3 Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Moderate to Severe Active Rheumatoid Arthritis A Single-arm, Open-label, Multiple-dose, Phase 3 Study to Evaluate Usability of SubcutaneousAuto-inj ... | Rheumatoid Arthritis | Biological: CT-P47 AI (tocilizumab);Biological: CT-P47 PFS (tocilizumab) | Celltrion | NULL | Not yet recruiting | 18 Years | 70 Years | All | 30 | Phase 3 | NULL |
| 2 | NCT04885829 (ClinicalTrials.gov) | May 31, 202120210531 | 3/5/202120210503 | Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers | A Single Dose, Double-Blind, Two-Period, Crossover, Comparative Pharmacokinetic Study of Three Tocilizumab Products Administered by the Subcutaneous Route to Normal Healthy Volunteers A Single Dose, Double-Blind, Two-Period, Crossover, Comparative Pharmacokinetic Study of Three Tocil ... | Rheumatoid Arthritis;Giant Cell Arteritis | Drug: Tocilizumab Prefilled Syringe | Syneos Health | Dr. Reddy's Laboratories Limited | Active, not recruiting | 18 Years | 50 Years | All | 300 | Phase 1 | Australia;India;New Zealand |
| 3 | NCT05090410 (ClinicalTrials.gov) | March 3, 202120210303 | 30/9/202120210930 | Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients ... | Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate: Comparative Study With Filgotinib and Tocilizumab Examined by Clinical Index as Well as Musculoskeletal Ultrasound Assessment Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients ... | Rheumatoid Arthritis;JAK Inhibitor;IL-6 Inhibitor;Musculoskeletal Ultrasound;Biomarker | Drug: filgotinib 200mg/day;Drug: subcutaneous tocilizumab 162mg/biweekly | Atsushi Kawakami | Gilead Sciences | Recruiting | 20 Years | N/A | All | 400 | Phase 3 | Japan |
| 4 | NCT03227419 (ClinicalTrials.gov) | January 22, 201820180122 | 19/7/201720170719 | Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders | Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial Abatacept Versus Tocilizumabby SubcutaneousAdministration for the Treatment of Rheumatoid Arthritis ... | Arthritis, Rheumatoid | Drug: Tocilizumab Prefilled Syringe;Drug: Abatacept Prefilled Syringe | Lille Catholic University | NULL | Recruiting | 18 Years | N/A | All | 224 | Phase 4 | France |
| 5 | EUCTR2017-000947-41-FR (EUCTR) | 18/08/201720170818 | 21/06/201720170621 | ORENCIA VERSUS ROACTEMRA BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS. ORENCIA VERSUS ROACTEMRA BY SUBCUTANEOUSADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ... | ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPEN-LABELED, SUPERIORITY TRIAL. - SUNSTAR ABATACEPT VERSUS TOCILIZUMABBY SUBCUTANEOUSADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS ... | Adults patients suffering from rheumatoid arthritis and in adequate response to a first line of treatment with a TNF alpha inhibitor. MedDRA version: 20.0;Level: HLT;Classification code 10039075;Term: Rheumatoid arthritis and associated conditions;System Organ Class: 100000004870;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Adults patients suffering from rheumatoid arthritis and in adequate response to a first line of trea ... | Trade Name: ORENCIA 125 mg, solution injectable en seringue préremplie Trade Name: RoActemra 162 mg solution injectable en seringue préremplie Trade Name: ORENCIA 125 mg, solution injectable en seringue préremplie Trade Name: RoActemra 162 mg s ... | Groupement des Hôpitaux de l’Institut Catholique de Lille | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 4 | France | |||
| 6 | NCT03155347 (ClinicalTrials.gov) | August 2, 201720170802 | 15/5/201720170515 | An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy An Efficacy and Safety Study of Subcutaneous Tocilizumabin Combination With Methotrexate (MTX) and a ... | A Randomized, Multi-Center, Double Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab (TCZ) in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current DMARD Therapy A Randomized, Multi-Center, Double Blind, Parallel-Group Study to Evaluate the Efficacy and Safety o ... | Rheumatoid Arthritis | Drug: Tocilizumab;Drug: MTX;Drug: Placebo Matched to MTX;Drug: Placebo Matched to Tocilizumab | Hoffmann-La Roche | NULL | Completed | 18 Years | 70 Years | All | 340 | Phase 3 | China |
| 7 | NCT02648035 (ClinicalTrials.gov) | September 22, 201620160922 | 5/1/201620160105 | EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis EMBRACE-SC: Observational Study of Subcutaneous(SC) TocilizumabAlone or in Combination With Conventi ... | Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Tocilizumab SC as Monotherapy or in Combination With cDMARD Treatment in RA Patients in Greece: the EMBRACE-SC Study. Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Toci ... | Rheumatoid Arthritis | Biological: Tocilizumab | Hoffmann-La Roche | NULL | Completed | 18 Years | N/A | All | 200 | Greece | |
| 8 | NCT02765074 (ClinicalTrials.gov) | June 30, 201620160630 | 19/4/201620160419 | Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumabin Rheum ... | Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of 12 Months Subcutaneous Tocilizumab in Rheumatoid Arthritis Phase IV Prospective Multicentrique Study Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of 12 Months Subcutaneous Tocilizum ... | Rheumatoid Arthritis | Drug: subcutaneous tocilizumab | Centre Hospitalier Régional d'Orléans | Rennes University Hospital | Recruiting | 18 Years | 85 Years | All | 60 | Phase 4 | France |
| 9 | NCT02659150 (ClinicalTrials.gov) | May 18, 201620160518 | 21/12/201520151221 | Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis Effect of SubcutaneousACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthri ... | A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of SubcutaneousACTEMRA on Inflamed ... | Rheumatoid Arthritis | Drug: tocilizumab | Massachusetts General Hospital | Brigham and Women's Hospital | Unknown status | 50 Years | 75 Years | Female | 21 | Phase 4 | NULL |
| 10 | NCT02608112 (ClinicalTrials.gov) | December 31, 201520151231 | 16/11/201520151116 | Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year | Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year Subcutaneous Tocilizumabin Monotherapy or in Combination With csDMARD in Patients With Moderate to S ... | Rheumatoid Arthritis | Drug: Methotrexate;Drug: Tocilizumab | Hoffmann-La Roche | NULL | Completed | 18 Years | N/A | All | 291 | France |